Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

References (7)

1. Winkler N, Strübing F, Groß W, Mier W, Ryschich E. Phenomenon of endothelial antibody capture: principles and potential for locoregional targeting of hepatic tumors. Hepatology 2018;68:1804-1816
2. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64:106-116
3. Itzykson R, Duchmann M, Lucas N, Solary E. CMML: Clinical and molecular aspects. Int J Hematol 2017;105:711-719
4. Rovira M, Cervantes F, Lozano M, Ribera JM, Reverter JC, Rozman C. Chronic myelomonocytic leukemia and solid neoplasms: is it a causal or a fortuitous association? Sangre (Barc) 1989;34:207-209
5. Budny A, Kozlowski P, Kaminska M, Jankiewicz M, Kolak A, Budny B, Budny W, Niemunis-Sawicka J, Szczypior G, Kurniawka B, Burdan F. Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski 2017;43:133-139
6. Tu J, Jia Z, Ying X, Zhang D, Li S, Tian F, Jiang G. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:5606
7. Muzykantov VR, Brenner JS. Vascular immunotargeting: take the highway to the first exit. Hepatology 2018;68:1672-1674.